Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressurenews2026-05-06T10:27:04+00:00May 6th, 2026|Endpoints News|
Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharmanews2026-05-05T19:01:07+00:00May 5th, 2026|Endpoints News|
Pfizer’s Albert Bourla says he has no mega-merger plansnews2026-05-05T18:16:42+00:00May 5th, 2026|Endpoints News|
BioNTech to scale down manufacturing, over 1,800 jobs on the linenews2026-05-05T16:53:50+00:00May 5th, 2026|Endpoints News|
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83Mnews2026-05-05T15:37:27+00:00May 5th, 2026|Endpoints News|
Swiss manufacturing, biotech industry so far unfazed by geopoliticsnews2026-05-05T14:55:55+00:00May 5th, 2026|Endpoints News|
Pfizer ends Trillium-related development as R&D spend jumpsnews2026-05-05T14:41:28+00:00May 5th, 2026|Endpoints News|
Microbiome startup raises $48M for immunotherapy and malnutrition treatmentsnews2026-05-05T14:30:41+00:00May 5th, 2026|Endpoints News|
J&J’s IBD combo fails Phase 2 studies, but will move into pivotal testingnews2026-05-05T14:30:26+00:00May 5th, 2026|Endpoints News|
